History of Alzheimer's

1211 words (5 pages) Essay

5th Sep 2017 Health Reference this

Disclaimer: This work has been submitted by a university student. This is not an example of the work produced by our Essay Writing Service. You can view samples of our professional work here.

Any opinions, findings, conclusions or recommendations expressed in this material are those of the authors and do not necessarily reflect the views of UKEssays.com.

Learning From Alzheimer’s

On November 25, 1901, Dr. Alois Alzheimer, a 37-year-old neuropathologist and psychiatrist at the Hospital for the Mentally Ill and for Epileptics in Frankfurt, Germany, examined a female patient with an unusual mental illness. Her symptoms included memory loss, language problems, and delusional behavior. After the patient died in 1906, Alzheimer examined her brain and found strange formations of the amyloid plaques and tau tangles.

Get Help With Your Essay

If you need assistance with writing your essay, our professional essay writing service is here to help!

Find out more

Today, Alzheimer’s disease is the sixth-leading cause of death in the United States. People with Alzheimer’s progressively lose memory, language skills, and the ability to perceive time and space. The risk of developing Alzheimer’s also increases with age. Like PD, the underlying disease of Alzheimer starts decade or more before diagnosis. While the exact mechanism by which the disease spread isn’t known, the pathology is driven by the aggregation of misfolded proteins – either amyloid-beta plaques or tau tangles, or both – with the damage spreading from neuron to neuron in a prion-like manner.

Alzheimer’s researchers have recently developed some ingenious tools to help track the disease in the living brain. In 2002, Chester Mathis and the psychiatrist William Klunk developed the PET imaging method to detect and measure amyloid-beta deposition in the brain of living Alzheimer’s patients. The method involves injecting patients with a radioactive tracer that can penetrate the blood-brain barrier and bind selectively to the amyloid-beta protein. The detectors surrounding the patient’s head capture the radiation emitted by the tracer and convert them into a picture that represents the relative amounts of plaque buildup in different parts of the brain.

PET imaging is an example of a biomarker, a metric that can quantify the progress of a disease in a living patient more sensitively than a clinical test like the UPDRS. No such imaging technique yet exists that can detect alpha-synuclein aggregates in the brains of people with PD.

Other potential biomarkers are chemical assays that estimate the amyloid content in a patient’s cerebrospinal fluid, circulating blood, and urine.

In the past decade, with the help of biomarkers, Alzheimer’s researchers have tested numerous drugs designed to target and break down amyloid-beta plaques. While some showed promise in open-label studies, they all failed when tested in phase 3 trials in patients with moderate to severe Alzheimer’s. One possible reason is that the drugs were given too late in the disease. To address that issue, Alzheimer’s researchers are working on three early-intervention studies.

The first involves an extended family in South America. They are descendants from an individual who carried a rare mutation, called the “Paisa” mutation, for a heritable form of Alzheimer’s disease. By late 20th century, the mutation had spread to around 5,000 people in the city of Medellin. This Alzheimer’s kindred came to the attention of the University of Antioquia neuroscientist Francisco Lopera. A simple genetic screening test can determine which kindred members possessed the bad gene. Those individuals with the bad gene could be given anti-amyloid-beta drugs long before they showed any cognitive impairments. Lopera’s project is part of the Alzheimer’s Prevention Initiative headed by the psychiatrist Eric Reiman at the Banner Alzheimer’s Institute in Phoenix, Arizona. In the trial, the Paisa volunteers get a baseline cognitive assessment plus a biomarker evaluation (involving PET imaging, cerebrospinal fluid analysis, and other assays) to measure the distribution of amyloid beta. They are given Genentech’s drug crenezumab, or a placebo. Researchers follow individuals for at least five years.

A second genetic study – also part of Banner’s Alzheimer’s Prevention Initiative – involves 1,300 currently healthy individuals age 60 to 75 in Europe and North America. Members of this cohort are at high risk of developing Alzheimer’s because they have been identified as carrying two copies of a gene called apolipoprotein E4. Such people are not guaranteed to develop Alzheimer’s like carriers of the Paisa mutation, but their risk is extremely high. Study subjects will receive either a placebo or one of two experimental drugs developed by the Swiss pharmaceutical company Novartis.

Find out how UKEssays.com can help you!

Our academic experts are ready and waiting to assist with any writing project you may have. From simple essay plans, through to full dissertations, you can guarantee we have a service perfectly matched to your needs.

View our services

The third study, known as the A4 trials, is supervised by Dr, Reisa Sperling of Harvard Medical School. It involves a cohort of 1,000 healthy individuals age 70 or older. The individuals in the group exhibit normal cognitive abilities but also have higher than normal levels of amyloid-beta plaques in their brains – as measured by a PET scan. This puts them at higher risk for developing Alzheimer’s. The question is, can that risk be reduced or eliminated?

***

PD researchers require imaging and other biomarkers for alpha-synuclein that enable scientists to identify people and also to monitor the disease as it progresses. Chester Mathis and his colleagues are developing a radiotracer that will bind to alpha-synuclein and yield a PET image for PD. The PET tracer is just one element in a bigger Fox Foundation project – the Parkinson’s Progression Marker Initiative. The idea is to follow several groups of people forward in time performing clinical exams, taking biological samples, and doing multiple imaging scans along the way.

Other researchers are looking elsewhere for Parkinson’s biomarkers that might allow for early diagnosis. Kathleen Shannon and her colleagues at Rush University Medical Center accessed old colon biopsies performed during routine colonoscopy procedures for three individuals who went on to develop PD. Because these biopsies were done two to five years before the onset of the PD motor symptoms, they provided an opportunity to see if alpha-synuclein was present in the gut before motor symptoms emerged.

Another possible place to look for alpha-synuclein is the submandibular gland. Charles Adler of the Mayo Clinic in Scottsdale, Arizona, biopsied the submandibular glands in twelve people with PD for more than five years and found Lewy pathology in nine of them.

The British mathematician Max Little has developed computer algorithms to analyze human voice recordings to detect irregular patterns in PD patients. His PD Voice Initiative uses phone call data as potential biomarkers to diagnose and measure the progression of PD.

Key Takeaways

Learning From Alzheimer’s

On November 25, 1901, Dr. Alois Alzheimer, a 37-year-old neuropathologist and psychiatrist at the Hospital for the Mentally Ill and for Epileptics in Frankfurt, Germany, examined a female patient with an unusual mental illness. Her symptoms included memory loss, language problems, and delusional behavior. After the patient died in 1906, Alzheimer examined her brain and found strange formations of the amyloid plaques and tau tangles.

Today, Alzheimer’s disease is the sixth-leading cause of death in the United States. People with Alzheimer’s progressively lose memory, language skills, and the ability to perceive time and space. The risk of developing Alzheimer’s also increases with age. Like PD, the underlying disease of Alzheimer starts decade or more before diagnosis. While the exact mechanism by which the disease spread isn’t known, the pathology is driven by the aggregation of misfolded proteins – either amyloid-beta plaques or tau tangles, or both – with the damage spreading from neuron to neuron in a prion-like manner.

Alzheimer’s researchers have recently developed some ingenious tools to help track the disease in the living brain. In 2002, Chester Mathis and the psychiatrist William Klunk developed the PET imaging method to detect and measure amyloid-beta deposition in the brain of living Alzheimer’s patients. The method involves injecting patients with a radioactive tracer that can penetrate the blood-brain barrier and bind selectively to the amyloid-beta protein. The detectors surrounding the patient’s head capture the radiation emitted by the tracer and convert them into a picture that represents the relative amounts of plaque buildup in different parts of the brain.

PET imaging is an example of a biomarker, a metric that can quantify the progress of a disease in a living patient more sensitively than a clinical test like the UPDRS. No such imaging technique yet exists that can detect alpha-synuclein aggregates in the brains of people with PD.

Other potential biomarkers are chemical assays that estimate the amyloid content in a patient’s cerebrospinal fluid, circulating blood, and urine.

In the past decade, with the help of biomarkers, Alzheimer’s researchers have tested numerous drugs designed to target and break down amyloid-beta plaques. While some showed promise in open-label studies, they all failed when tested in phase 3 trials in patients with moderate to severe Alzheimer’s. One possible reason is that the drugs were given too late in the disease. To address that issue, Alzheimer’s researchers are working on three early-intervention studies.

The first involves an extended family in South America. They are descendants from an individual who carried a rare mutation, called the “Paisa” mutation, for a heritable form of Alzheimer’s disease. By late 20th century, the mutation had spread to around 5,000 people in the city of Medellin. This Alzheimer’s kindred came to the attention of the University of Antioquia neuroscientist Francisco Lopera. A simple genetic screening test can determine which kindred members possessed the bad gene. Those individuals with the bad gene could be given anti-amyloid-beta drugs long before they showed any cognitive impairments. Lopera’s project is part of the Alzheimer’s Prevention Initiative headed by the psychiatrist Eric Reiman at the Banner Alzheimer’s Institute in Phoenix, Arizona. In the trial, the Paisa volunteers get a baseline cognitive assessment plus a biomarker evaluation (involving PET imaging, cerebrospinal fluid analysis, and other assays) to measure the distribution of amyloid beta. They are given Genentech’s drug crenezumab, or a placebo. Researchers follow individuals for at least five years.

A second genetic study – also part of Banner’s Alzheimer’s Prevention Initiative – involves 1,300 currently healthy individuals age 60 to 75 in Europe and North America. Members of this cohort are at high risk of developing Alzheimer’s because they have been identified as carrying two copies of a gene called apolipoprotein E4. Such people are not guaranteed to develop Alzheimer’s like carriers of the Paisa mutation, but their risk is extremely high. Study subjects will receive either a placebo or one of two experimental drugs developed by the Swiss pharmaceutical company Novartis.

The third study, known as the A4 trials, is supervised by Dr, Reisa Sperling of Harvard Medical School. It involves a cohort of 1,000 healthy individuals age 70 or older. The individuals in the group exhibit normal cognitive abilities but also have higher than normal levels of amyloid-beta plaques in their brains – as measured by a PET scan. This puts them at higher risk for developing Alzheimer’s. The question is, can that risk be reduced or eliminated?

***

PD researchers require imaging and other biomarkers for alpha-synuclein that enable scientists to identify people and also to monitor the disease as it progresses. Chester Mathis and his colleagues are developing a radiotracer that will bind to alpha-synuclein and yield a PET image for PD. The PET tracer is just one element in a bigger Fox Foundation project – the Parkinson’s Progression Marker Initiative. The idea is to follow several groups of people forward in time performing clinical exams, taking biological samples, and doing multiple imaging scans along the way.

Other researchers are looking elsewhere for Parkinson’s biomarkers that might allow for early diagnosis. Kathleen Shannon and her colleagues at Rush University Medical Center accessed old colon biopsies performed during routine colonoscopy procedures for three individuals who went on to develop PD. Because these biopsies were done two to five years before the onset of the PD motor symptoms, they provided an opportunity to see if alpha-synuclein was present in the gut before motor symptoms emerged.

Another possible place to look for alpha-synuclein is the submandibular gland. Charles Adler of the Mayo Clinic in Scottsdale, Arizona, biopsied the submandibular glands in twelve people with PD for more than five years and found Lewy pathology in nine of them.

The British mathematician Max Little has developed computer algorithms to analyze human voice recordings to detect irregular patterns in PD patients. His PD Voice Initiative uses phone call data as potential biomarkers to diagnose and measure the progression of PD.

Key Takeaways

  • Alzheimer’s researchers have developed some ingenious tools to help track the disease in the living brain.
    To address the issue that the drugs were given too late in the disease in human drug trials, Alzheimer’s researchers are working on three early-intervention studies.
  • Inspired by the Alzheimer’s researchers, PD researchers are working on multiple fronts to develop biomarkers to track PD in the living brain.

Cite This Work

To export a reference to this article please select a referencing stye below:

Reference Copied to Clipboard.
Reference Copied to Clipboard.
Reference Copied to Clipboard.
Reference Copied to Clipboard.
Reference Copied to Clipboard.
Reference Copied to Clipboard.
Reference Copied to Clipboard.

Related Services

View all

DMCA / Removal Request

If you are the original writer of this essay and no longer wish to have your work published on the UKDiss.com website then please: